STALEVO 200 MG
ENTACAPONE : 200 MG CARBIDOPA : 31.25 MG LEVODOPA : 125 MG · DIN 02337835 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is STALEVO?
STALEVO 200 MG contains ENTACAPONE : 200 MG CARBIDOPA : 31.25 MG LEVODOPA : 125 MG. It is listed in the Health Canada Drug Product Database under DIN 02337835, held by SANDOZ CANADA INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Jul-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02337835 |
|---|---|
| Brand name | STALEVO |
| Generic / active ingredient | ENTACAPONE : 200 MG CARBIDOPA : 31.25 MG LEVODOPA : 125 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR |
| AHFS class | 28:36.12 ; 28:36.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Jul-2020 |
| Original market date | 2010-01-20 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N04BA03 LEVODOPA,DECARBOXYLASE INHIBITOR, AND COMT INHIBITOR. 5 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| STALEVO | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02305933 |
| STALEVO | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02305941 |
| STALEVO | 37.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02305968 |
| STALEVO | 75 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02337827 |
| LEVODOPA, CARBIDOPA AND ENTACAPONE TABLETS | 37.5 MG | TABLET | STRIDES PHARMA CANADA INC | APPROVED | DIN 02517884 |
| LEVODOPA, CARBIDOPA AND ENTACAPONE TABLETS | 50 MG | TABLET | STRIDES PHARMA CANADA INC | APPROVED | DIN 02517876 |
| SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE | 125 MG | TABLET | SANDOZ CANADA INCORPORATED | APPROVED | DIN 02498871 |
| SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE | 150 MG | TABLET | SANDOZ CANADA INCORPORATED | APPROVED | DIN 02498901 |
| SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | APPROVED | DIN 02498898 |
| SANDOZ LEVODOPA-CARBIDOPA-ENTACAPONE | 25 MG | TABLET | SANDOZ CANADA INCORPORATED | APPROVED | DIN 02498863 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.